IceCure Medical
Caesarea
About IceCure Medical
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, IceCure’s core technology is based on cryoablation. Its proprietary third-generation technology uses freezing temperatures (liquid nitrogen) to effectively destroy tumors safely, quickly, and painlessly, without the need for surgery. Commercially available in the U.S.A., Europe, Hong-Kong, Thailand, Singapore and South- Central America, its flagship system, ProSense™, uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The easy-to-use ProSense™ cryoablation procedure enables full physician control and can be performed in less than 30 minutes in the comfort of a doctor’s office. As a proven solution for the treatment of fibroadenomas (benign breast tumors), the ProSense system is also indicated for use in the fields of general surgery, oncology, gynecology and urology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $78.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: tlv:ICCM
- Website: icecure-medical.com
- Phone: 97246230222
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/icecure-medical-99328 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.